Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20523552 | 0.82 | EPHX2 (0.30) | — | |
| SCHEMBL19557881 | 0.76 | MAPT (0.32) | MAPTLMNAALDH1A1PKML3MBTL1 | |
| SCHEMBL20053912 | 0.76 | MAPT (0.32) | MAPTLMNAALDH1A1PKML3MBTL1 | |
| SCHEMBL10770145 | 0.76 | LMNA (0.30) | MAPTLMNA | |
| SCHEMBL25047557 | 0.71 | MPO (0.34) | — | |
| SCHEMBL13129994 | 0.71 | NOS1 (0.38) | MAPTALDH1A1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL30716649 | 0.70 | GABRA1 (0.48) | — | |
| SCHEMBL15652485 | 0.69 | KIT (0.49) | MAPTLMNAALDH1A1PKML3MBTL1 | |
| SCHEMBL23210319 | 0.69 | — | — | |
| SCHEMBL23229773 | 0.69 | PDK2 (0.39) | MAPTLMNAALDH1A1PKML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025038863-A1 | INDOLE AND PYRROLOYPYRIDINE DERIVATIVES AS GPR17 MODULATORS | BIOGEN MA INC. (US) | 2025-02-20 | — | — | WO | disclosed |
| CN-118359634-A | Pyrazole derivative and medical use thereof | 正大天晴药业集团股份有限公司 | 2024-07-19 | — | — | CN | disclosed |
| US-20230365592-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | HALIA THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-11578061-B2 | Inhibitors of LRRK2 kinase | Halia Therapeutics, Inc. (US) | 2023-02-14 | — | — | US | disclosed |
| EP-3941922-A1 | INHIBITORS OF RAF KINASES | Kinnate Biopharma Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| CN-113874381-A | Inhibitors of RAF kinase | 金耐特生物制药公司 | 2021-12-31 | — | — | CN | disclosed |
| WO-2021147952-A1 | PYRIMIDOPYRROLE COMPOUND | 江苏先声药业有限公司 | 2021-07-29 | — | — | WO | disclosed |
| EP-3774782-A2 | ATF6 INHIBITORS AND USES THEREOF | Black Belt TX Ltd (GB) | 2021-02-17 | — | — | EP | disclosed |
| WO-2020198058-A1 | INHIBITORS OF RAF KINASES | KINNATE BIOPHARMA INC. (US) | 2020-10-01 | — | — | WO | disclosed |
| WO-2020198058-A1 | INHIBITORS OF RAF KINASES | KINNATE BIOPHARMA INC. (US) | 2020-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | LRRK2, SNCA, PRKAR2B | MAPT 422/4885LMNA 532/4885ALDH1A1 2661/4885 |
| US-20230365592-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | PAH, KDM8, PHF8 | MAPT 2359/4885LMNA 798/4885ALDH1A1 865/4885 |
| US-11578061-B2 | Inhibitors of LRRK2 kinase | LRRK2, SNCA, PRKAR2B | MAPT 422/4885LMNA 532/4885ALDH1A1 2661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.